Effect of paliperidone palmitate treatment on disease family burden and rehabilitation effect in community schizophrenic patients / 上海预防医学

ObjectiveTo explore the effect of paliperidone palmitate treatment on schizophrenic patients in the community. Methods446 schizophrenic patients who used paliperidone palmitate injection were selected in Shanghai. Before and after the treatment， the disease family burden scale， the concise evaluation scale of drug treatment compliance， the VAS100 score of treatment satisfaction， the short form of quality of life measurement scale， and the screening scale of social function defects were used to evaluate the effects of paliperidone palmitate injection. The data were statistically analyzed using SPSS 26.0 software. ResultsAfter using paliperidone palmitate injection， the total score of family burden （13.94±12.17）， the score of daily family activities （3.26±2.74）， the score of family entertainment activities （2.21±2.30）， and the score of family relationship （2.79±2.76） were significantly higher than those before the treatment （14.98±12.64， 3.51±2.88， 2.48±2.38， 3.11±2.87， respectively， all with P<0.05）. The scores of the World Health Organization on quality of life brief scale （62.89±11.94） and the medication compliance scale （28.11±5.64） were better than those before treatment （60.67±12.62 and 27.37±6.96， all with P<0.05）. Compared with the prior treatment without paliperidone palmitate injection， the number of readmissions after treatment was significantly reduced （P<0.01）. ConclusionThe treatment of paliperidone palmitate injection has significant effect， which can effectively reduce the disease family burden of Schizophrenic patients， improve their quality of life， enhance their drug compliance， reduce the readmission rate of patients， ensure long-term treatment effect and promote disease recovery.

Effects of paliperidone palmitate long-acting injection on clinical symptoms and social function in patients with schizophrenia in communities / 中华行为医学与脑科学杂志

Objective:To understand the effects of paliperidone palmitate (PP) long-acting injection on hospitalization, psychiatric symptoms, individual and social function of community patients with schizophrenia.Methods:From March 2021 to September 2022, 239 patients with schizophrenia in the community of Zhongshan city were treated with PP injection in a 1-month dosage form for 1 year.The hospitalization rate was compared before and after the treatment.The brief psychiatric rating scale (BPRS), modified overt aggression scales(MOAS), clinical global impressions-severity(CGI-S), and personal and social performance scale (PSP) were used to evaluate psychiatric symptoms and personal social function at baseline, at the end of the 8th week, the end of the 6th month and the end of the 12th month after treatment.Repeated measurement analysis of variance was used to compare the results at different times of treatment, and Logistic regression analysis was used to analyze the factors affecting treatment by SPSS 26.0.Results:One year after treatment the number of hospitalization was lower than that before (0(1) times, 0(0) times)( Z=-4.43, P<0.01), and the hospitalization days was lower than before (43(83.3) days, 0(0) days)( Z=-8.65, P<0.01) for the schizophrenic patients.The total BPRS score for schizophrenic patients decreased from (45.3±9.2) to (27.5±9.0) after 1 year of treatment( χ2=465.20, P<0.01), and the external aggressive behavior score was lower than the baseline score (1(7), 0(0))( F=308.36, P<0.01). The total effective rates were 30.5%(73/239), 77.4%(185/239) and 81.6%(195/239) after 8 weeks, 6 months and 1 year of treatment, respectively.The impairment in the four aspects of personal and social functioning were improved to varying degrees (all P<0.01). The severity of the disease was reduced 1 year after treatment.And the proportions of partial to very severe, moderate, none or mild were 10.0%(24/239), 56.5%(135/239), and 33.5%(80/239). Ordinal logistic regression analysis showed that younger age at treatment ( β=-0.08, OR=0.93, 95% CI=0.87-0.99) and older age at first onset ( β=0.07, OR=1.07, 95% CI=1.01-1.14) were associated with better treatment outcomes. Conclusion:Long-term injection of paliperidone palmitate can effectively improve the mental symptoms and individual social function of community patients with schizophrenia.

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Objective: To analyze the efficacy and safety of paliperidone palmitate 3-monthly (PP3M) in Latin American patients with schizophrenia vs. rest-of-world (ROW). Methods: We analyzed data from two multinational, double-blind (DB), randomized, controlled phase 3 studies including patients with schizophrenia (DSM-IV-TR) previously stabilized on PP1M/PP3M (open-label [OL] phase). Patients were randomized to PP3M or PP1M (noninferiority study A) and PP3M or placebo (study B) in DB phase. The subgroup analysis included Latin American (Argentina, Brazil, Colombia, Mexico) patients. Primary efficacy endpoints were relapse-free rates (study A) and time-to-relapse (study B). Results: In study A, 63/71 (88.7%) and in study B 38/43 (88.4%) Latin American patients completed the DB phase. In study A, relapse-free percentage was similar in Latin America (PP3M: 97%, PP1M: 100%) and ROW (PP3M: 91%, PP1M: 89%). In study B, median time-to-relapse was not estimable in the Latin American subgroup for either placebo or PP3M groups, nor for the ROW PP3M group; the median time-to-relapse in the ROW placebo group was 395 days. Caregiver burden improved in patients switching from oral antipsychotics (OL baseline) to PP3M/PP1M in DB phase (Involvement Evaluation Questionnaire score mean ± SD change, -9.4±15.16; p < 0.001). Treatment emergent adverse events with PP3M during DB phase were similar in Latin America (study A: 24/34 [70.6%]; study B: 15/21 [71.4%]) and ROW (study A: 318/470 [67.7%]; study B: 84/139 [60.4%]) subgroups. Conclusion: PP3M was efficacious and showed no new safety concerns in patients with schizophrenia from Latin America, corroborating ROW findings. Clinical trial registration: NCT01515423, NCT01529515

Effect of paliperidone palmitate long-acting injection on the expression of miR-132 and miR-320 in serum of schizophrenic patients / 中国基层医药

Objective@#To investigate the therapeutic effect of long-acting paliperidone palmitate on schizophrenia and the expression of miR-132 and miR-320 in serum of patients with schizophrenia.@*Methods@#From January 2016 to December 2018, 68 patients with schizophrenia in Wenzhou Kangning Hospital were selected as treatment group.Sixty healthy people were selected as control group.The blood was taken before treatment and 12 months after treatment.The positive and negative symptom scales (PANSS) was recorded and evaluated, and the effect of long-acting injection of paliperidone palmitate on the expression of miR-132 and miR-320 in serum of patients with schizophrenia was detected by RT-PCR.@*Results@#Three months after treatment, the PANSS scores of the treatment group were significantly lower than those of the case group [(60.2±5.4)points vs.(84.5±4.7)points, t=12.02, 22.52, 27.16, 33.32, all P<0.01]. With the prolongation of treatment time, the treatment effect was most obvious at 12 months[(38.2±1.8)points]. The results of RT-PCR showed that compared with the control group [(1.74±0.92)%, (1.43±1.01)%], the expression of serum miR-132 and miR-320 in the treatment group was significantly decreased [(0.47±0.32)%, (0.53±0.37)%, t=13.96, 14.93, all P<0.01]. The long-acting injection of paliperidone palmitate significantly increased the expression of miR-132 and miR-320 in serum of patients with schizophrenia[(0.96±0.58), (1.16±1.07), t=11.08, 8.45, all P<0.01].@*Conclusion@#Long-acting paliperidone palmitate has a certain therapeutic effect on schizophrenia and can up-regulate the expression of miR-132 and miR-320 in serum of patients with schizophrenia.

The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study

OBJECTIVE: Whether long-acting injectable antipsychotics (LAI) are superior to oral antipsychotics remains a controversial question, and results vary depending on the study design. Our study was performed to compare outcomes of oral anti-psychotics and paliperidone palmitate (PP) in clinical practice by investigating the numbers of admissions and bed days. METHODS: We performed a retrospective observational mirror-image study at a single medical center, reviewing medical charts to obtain the clinical data. Forty-six patients with a diagnosis of schizophrenia or schizoaffective disorder who had received at least two doses of PP were included in the analysis. The Wilcoxon signed-rank test was used to compare the numbers of bed days and admissions 1 year before starting PP with those numbers at 1 year after. RESULTS: The mean number of admissions fell from 0.83 to 0.17 per patient (p < 0.0002), and the median fell from 1 to 0. The mean number of bed days decreased significantly, from 24.85 to 8.74 days (p < 0.006). The outcomes remained similar in sensitivity analyses set up with different mirror points. CONCLUSION: Our results indicate that initiating PP reduced the mean numbers of hospital admissions and bed days compared with prior oral medication. LAIs may thus be cost effective in practice; its use bringing about cost reductions greater than its purchase cost.

Effect of paliperidone palmitate long－acting injection on the expression of miR－132 and miR－320 in serum of schizophrenic patients / 中国基层医药

Objective To investigate the therapeutic effect of long －acting paliperidone palmitate on schizophrenia and the expression of miR －132 and miR －320 in serum of patients with schizophrenia.Methods From January 2016 to December 2018,68 patients with schizophrenia in Wenzhou Kangning Hospital were selected as treatment group.Sixty healthy people were selected as control group.The blood was taken before treatment and 12 months after treatment.The positive and negative symptom scales ( PANSS) was recorded and evaluated ,and the effect of long－acting injection of paliperidone palmitate on the expression of miR －132 and miR－320 in serum of patients with schizophrenia was detected by RT －PCR.Results Three months after treatment ,the PANSS scores of the treatment group were significantly lower than those of the case group [( 60.2 ±5.4 ) points vs.( 84.5 ± 4.7)points,t＝12.02,22.52,27.16,33.32,all P＜0.01].With the prolongation of treatment time ,the treatment effect was most obvious at 12 months[(38.2 ±1.8)points].The results of RT－PCR showed that compared with the control group [(1.74 ±0.92)%,( 1.43 ±1.01)%],the expression of serum miR －132 and miR －320 in the treatment group was significantly decreased [(0.47 ±0.32)%,(0.53 ±0.37)%,t＝13.96,14.93,all P＜0.01]. The long －acting injection of paliperidone palmitate significantly increased the expression of miR －132 and miR－320 in serum of patients with schizophrenia [(0.96 ±0.58),(1.16 ±1.07),t＝11.08,8.45,all P＜0.01]. Conclusion Long－acting paliperidone palmitate has a certain therapeutic effect on schizophrenia and can up －regulate the expression of miR－132 and miR－320 in serum of patients with schizophrenia.

Clinical effects of case care management combined with Paliperidone palmitate in treatment of patients with schizophrenia treated / 中国生化药物杂志

Objective To study and analyze the clinical effect of case care management in patients with schizophrenia treated with Paliperidone palmitate. Methods 90 patients with schizophrenia in the third People's hospital of Huzhou were selected as the subjects. The patients in the experimental group and the control group were treated with Paliperidone palmitate for 12 months. The control group was given routine nursing, the experimental group was given case nursing management, health education, professional psychological counseling, paying close attention to the clinical symptoms of patients, seminars, encouraging patients to contact the society, regular analysis of problems. PANSS score and MARS score and other clinical indicators of the experimental group and the control group of patients were compared and analyzed. Results After treatment, the medication compliance score of the experimental group was (7.32±0.34) points, significantly higher than that (5.12±0.23) points of the control group with statistical significance (P<0.05). The score of PANSS in the control group was (42.90±3.87) points, and the score of PANSS in the experimental group was (36.78±3.32) points, and the difference between the two groups was statistically significant (P<0.05). Conclusion nursing case management plus Paliperidone palmitate treatment in patients with schizophrenia has good clinical curative effect, could significantly improve the clinical symptoms of patients, help patients recovery, has clinical application significance.

Comparative Study on 2 Kinds of Paliperidone Preparations in the Treatment of Schizophrenia / 中国药房

OBJECTIVE:To compare Paliperidone sustained-release tablet and Paliperidone palmitate injection in the treatment of schizophrenia in respects of medium-term and long-term efficacy,safety,insight,medication compliance and social function of patients,so ad to provide reference for drug selection in the clinic.METHODS:Eighty-four schizophrenia patients selected from our center during Mar.2015-Jun.2016 were divided into Paliperidone sustained-release tablet group (group H,44 cases) and Paliperidone palmitate injection group (group Z,40 cases).Group H was given Paliperidone sustained-release tablet orally with initial dose of 3 mg/d,gradually increasing to 9 mg/d 2 weeks later according to disease condition;the drug dose was adjusted and ranged 3-12 mg/d according to disease condition.Group Z was given Paliperidone palmitate injection intramuscularly,150 mg on 1st day,100 mg on 8th day,and then given injection once a month,drug dose was adjusted according to disease condition (75,100,150 mg).Treatment course of 2 groups lasted for 12 months.Before treatment,1,2,3,6,9,12 months after treatment,Positive and Negative Syndrome Scale (PANSS) was used to evaluate therapeutic efficacy;Scale to Assess Unawareness of Mental Disorder (SAUMD) was used to evaluate the cognition of patients to disease;Medication Adherence Rating Scale (MARS) was used to evaluate medication compliance;Personal and Social Performance Scale (PSP) was used to evaluate patient's social function.The occurrence of ADR was observed during treatment.RESULTS:3,2 patients withdrew from group H,Z during treatment.Before treatment,there was no statistical significance in PANSS,SAUMD,MARS,PSP scores between 2 groups (P＞0.05).1,2,3,6,9,12 months after treatment,PANSS and SAUMD scores of 2 groups were decreased significantly,while MARS and PSP scores were increased significantly,compared to before treatment,with statistical significance (P＜0.05).9,12 months after treatment,PANSS and SAUMD scores of group Z were decreased significantly,while MARS and PSP scores were increased significantly,compared to group H,with statistical significance (P＜0.05).There was no statistical significance in the occurrence of ADR between 2 groups (P＞0.05).CONCLUSIONS:For schizophrenia,Paliperidone palmitate injection is better than Paliperi done sustained-release tablet in respects of medium-term and long-term efficacy,patient's insight,medication compliance,social function recovery;the longer the time,the more prominent the superiority.There is no significant difference in safety between them.

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report

Peripheral edema is observed as an adverse effect of the usage of antipsychotics in the literature. This case report describes a 36-year-old female patient with the diagnosis of paranoid schizophrenia who presented with pretibial edema following initiation of long-acting injectable paliperidone palmitate. Pretibial edema developed within the second week of treatment and completely disappeared after its discontinuation.

Clinical effects of case care management combined with Paliperidone palmitate in treatment of patients with schizophrenia treated / 中国生化药物杂志

Objective To study and analyze the clinical effect of case care management in patients with schizophrenia treated with Paliperidone palmitate. Methods 90 patients with schizophrenia in the third People's hospital of Huzhou were selected as the subjects. The patients in the experimental group and the control group were treated with Paliperidone palmitate for 12 months. The control group was given routine nursing, the experimental group was given case nursing management, health education, professional psychological counseling, paying close attention to the clinical symptoms of patients, seminars, encouraging patients to contact the society, regular analysis of problems. PANSS score and MARS score and other clinical indicators of the experimental group and the control group of patients were compared and analyzed. Results After treatment, the medication compliance score of the experimental group was (7.32±0.34) points, significantly higher than that (5.12±0.23) points of the control group with statistical significance (P<0.05). The score of PANSS in the control group was (42.90±3.87) points, and the score of PANSS in the experimental group was (36.78±3.32) points, and the difference between the two groups was statistically significant (P<0.05). Conclusion nursing case management plus Paliperidone palmitate treatment in patients with schizophrenia has good clinical curative effect, could significantly improve the clinical symptoms of patients, help patients recovery, has clinical application significance.

Five Month-Persistent Extrapyramidal Symptoms following a Single Injection of Paliperidone Palmitate: A Case Report

Long-acting injectable (LAI) antipsychotics are useful in the treatments for schizophrenic patients with poor adherence due to their maintaining feature of therapeutic plasma level without daily administrations. However, their long-lasting property can cause complicated problems such as a long-lasting side effect. We report a patient who experienced LAI-induced extrapyramidal symptoms (EPSs) for 5 months after a single injection. During that period, every trial to ameliorate this condition turned out to be a failure. The 3-month formulation of paliperidone palmitate is now close at hand. We have to be aware of possible long-lasting adverse events and confirm the tolerability to LAI before use.

Monitoring of Plasma Concentration and Analysis of Influential Factors for Paliperidone Palmitate Injection in 37 Patients with Schizophrenia / 中国药房

OBJECTIVE:To explore the influential factors for plasma concentration of paliperidone palmitate injection for pa-tients with schizophrenia. METHODS:37 schizophrenia patients who used Paliperidone palmitate injection and took plasma concentra-tion monitoring in Wuxi Mental Health Center from Sept. 2012 to Jun. 2015 was selected,the results were statistically analyzed,and the influential factors were preliminary explored. RESULTS:Totally 37 times were conducted for the plasma concentration monitoring for paliperidone with the average plasma concentration of(17.72±13.46)ng/ml,and 24 times(accounting for 64.86%)in the range of(10-60 ng/ml);the average plasma concentration of male patients was lower than that of female patients,the difference was statisti-cally significant(P0.05);there was also no significant difference in plasma concentration/dose ratio in patients with different daily dose(P>0.05);the average plasma concentration of patients with combination treatment was higher than that of single drug,the difference was statistically signifi-cant(P0.05). CONCLUSIONS:The plasma concentration of paliperidone palmitate is affected by age,combination treat-ment and other factors,clinic can optimize the therapeutic regimen based on monitoring results of plasma concentration and patients’ symptoms to promote the rational drug use.

Preparation and release of paliperidone palmitate injection: A study / 国际药学研究杂志

Objective: To prepare paliperidone palmitate injection, establish the testing method for its release rate, and validate the methodology. Methods: Wet grinding was used to prepare paliperidone palmitate injection, high performance liquid chromatography was adopted to establish release rate detection, and validate its methodology. Results: The average particle diameter of home-made agent was about 1 µm, and it was an irregular bulk observed under transmission electron microscope; the precision of established release rate detection was 1.5%, recovery rate was 100.70% and stability RSD was 0.33%. The average release rate in vitro of home-made agent in three batches was: 8.00% in 1.5min, 62.26% in 20 min, and 85.44% in 45 min. Conclusion: The particle size distribution and release rate of prepared sustained-release injection are consistent with those of original research, and the testing method of release rate is simple, sensitive and accurate, which could effectively monitor the product quality. The average release rates of agent in three batches are within the scope of quality standards.

Preparation and release of paliperidone palmitate injection:a study / 国际药学研究杂志

Objective To prepare paliperidone palmitate injection,establish the testing method for its release rate,and vali?date the methodology. Methods Wet grinding was used to prepare paliperidone palmitate injection,high performance liquid chroma?tography was adopted to establish release rate detection,and validate its methodology. Results The average particle diameter of home-made agent was about 1μm,and it was an irregular bulk observed under transmission electron microscope;the precision of es?tablished release rate detection was 1.5%,recovery rate was 100.70%and stability RSD was 0.33%. The average release rate in vitro of home-made agent in three batches was:8.00%in 1.5min,62.26%in 20 min,and 85.44%in 45 min. Conclusion The particle size distribution and release rate of prepared sustained-release injection are consistent with those of original research,and the testing method of release rate is simple,sensitive and accurate,which could effectively monitor the product quality. The average release rates of agent in three batches are within the scope of quality standards.

A Case of Ileus in a Patient with Schizophrenia Under Paliperidone Palmitate Treatment

Constipation is a side effect of antipsychotic drugs that have high affinity for muscarinic cholinergic receptors. In addition, ileus is an important side effect of antipsychotic treatment, with potentially morbid and mortal consequences if early detection fails. In this report, a colonic ileus case is described in a patient with schizophrenia under the treatment of paliperidone palmitate. Consequently, complete physical examination and close screening of side effects are recommended when antipsychotics are prescribed.

Paliperidone Palmitate-induced Urinary Incontinence: A Case Report

Urinary incontinence, although rarely reported, is one of the most important adverse effects of antipsychotic medication. It can be an embarrassing, distressing, and potentially treatment-limiting. Several antipsychotics, including both typical and atypical varieties, are known to induce urinary incontinence. Many antipsychotic drugs target the neural pathways controlling continence by binding to receptors of some neurotransmitters such as serotonin, dopamine, acetylcholine, and adrenaline. Pharmacological management of incontinence should be considered if there is a risk of cessation of the antipsychotic therapy or any decline in patients' compliance. Amitriptyline, desmopressin, ephedrine, and anticholinergics such as oxybutynin and trihexyphenidyl are the most frequently used agents to treat incontinence. We think that the frequency of incontinence is higher than reported in the literature, and that follow-up routines should include a form of standardized screening for all possible adverse effects, including incontinence, of any given antipsychotic. In this article, we report a case of urinary incontinence as an adverse effect of paliperidone palmitate use during maintenance therapy in a patient with schizophrenia.

Paliperidone Palmitate In Adolescents, Is There A Role?: A Case Report

Objective: Currently, paliperidone palmitate is not approved for the treatment of schizophrenia in adolescents. It is only indicated for treatment of schizophrenia and schizoaffective disorder in adults. This case report highlights the successful treatment outcome with paliperidone palmitate in an adolescent with schizophrenia. Methods: We report a case of an adolescent who presented with psychotic symptoms and marked deterioration in functioning over a period of one year. Results: She showed significant improvement in functioning, and her psychotic symptoms gradually subsided with paliperidone palmitate. Conclusions: Paliperidone palmitate could be considered as an effective treatment modality in adolescents with schizophrenia.

The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection / 신경정신의학

OBJECTIVES: The aim of this study was to examine the drug adherence and treatment effect of the paliperidone long acting injection (LAI) in patients with schizophrenia or other psychotic disorders. METHODS: We reviewed the medical charts of patients who were prescribed paliperidone LAI from January 2010 to April 2014. Date of each injection, last observation, and first admission after use of the drug were obtained. Kaplan-Meier survival analysis was used for calculation of drug adherence. The dose of paliperidone LAI, concurrent oral antipsychotics, and anticholinergic agent was also obtained. Antipsychotics dose was calculated as olanzapine equivalent dose. RESULTS: The drug adherence of the paliperidone LAI on day 365 was 65%. The reasons for all cause discontinuation were follow-up loss, no effect, poor insight, rejection, extrapyramidal symptom, pain, etc. A total dose of 9.1 mg of oral antipsychotics was decreased, while the dose of anticholinergic agent was increased. CONCLUSION: The drug adherence of the paliperidone LAI was 65%, which was concordant with previous studies. The dose of concurrent oral antipsychotics was increased, while the dose of anticholinergic agent was decreased.

Efficacy and safety of paliperidone palmitate in the treatment of schizophrenia: a Meta-analysis / 中国药学杂志

OBJECTIVE: To evaluate the efficacy and safety of paliperidone palmitate long-acting injection (PP-LAI) in the treat-i lent of schizophrenia. METHODS: Published studies concerning PP-LAI for schizophrenia were searched systemically and assessed liy Jadad items. RevMan 5.2 software was used for data analysis and for calculating effectiveness and their 95% CIs. RESULTS: Twelve Clinical random control trials including 39 analytic sets were selected for Meta-analysis. The incidence of efficient cases in PP-LAI group was 1.7 (95% CI; 1.50-1.91) times higher than that in placebo group (Z=8.55, P<0.01) and equaled to the rate in risperidone group (RR=1, 95% CI: 0.88-1.13). Compared with the control group of placebo (RR=1.01, 95% CI: 0.97-1.05) t.nd risperidone (RR=1.07, 95% CI; 0.98-1.16), PP-LAI seemed to be well tolerated, with the same incidence of adverse e-vents. CONCLUSION: Paliperidone palmitate has certain efficacy and safety in the treatment of schizophrenia.

A Rapid, Stability Indicating RP-UPLC Method for Determination of Paliperidone Palmitate in a Depot Injectable Formulation.

A rapid, stability-indicating reversed phase ultra-performance liquid chromatographic (RP-UPLC) method was developed for the determination of paliperidone palmitate (PP), in depot injectable dosage form. The chromatographic separation was achieved on an Acquity BEH C18 (50 mm × 2.1 mm, 1.7 μm) column, with a mobile phase consisting of ammonium acetate buffer, and acetonitrile at a ratio of 10:90 (v/v) and a flow rate of 0.6 mL/min. The eluted compound was monitored at a wavelength of 238 nm using a UV detector. The method described herein separated paliperidone palmitate from all other formulation components and two major known degradation products (N-Oxide and paliperidone) within a run time of 2.5 min. The method also generated linear results over a PP concentration range of 156 to 468 μg/mL. The stability indicating capability of the method was established by performing forced degradation experiments. The RP-UPLC method that was developed was validated according to the International Conference on Harmonization (ICH) guidelines. This method was successfully applied in the quantitative determination of PP in a stability study of paliperidone palmitate depot injection. The procedure described herein is simple, selective, and reliable for routine quality control analysis as well as stability testing.